160 related articles for article (PubMed ID: 38573492)
1. SNHG4-mediated PTEN destabilization confers oxaliplatin resistance in colorectal cancer cells by inhibiting ferroptosis.
Li SQ; Xu WT; Yin YX; Wei HT; Li KZ; Xie MZ; Lv F; Xie LY; Hu BL
Apoptosis; 2024 Jun; 29(5-6):835-848. PubMed ID: 38573492
[TBL] [Abstract][Full Text] [Related]
2. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
[TBL] [Abstract][Full Text] [Related]
3. Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin.
Yang C; Zhang Y; Lin S; Liu Y; Li W
Aging (Albany NY); 2021 Mar; 13(10):13515-13534. PubMed ID: 33819186
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway.
Zhang Y; Liu X; Zhang J; Xu Y; Shao J; Hu Y; Shu P; Cheng H
Aging (Albany NY); 2020 Mar; 12(7):5640-5650. PubMed ID: 32209726
[TBL] [Abstract][Full Text] [Related]
5. lncRNA SNHG4 modulates colorectal cancer cell cycle and cell proliferation through regulating miR-590-3p/CDK1 axis.
Zhou Z; Tan F; Pei Q; Li C; Zhou Y; Li Y; Pei H
Aging (Albany NY); 2021 Mar; 13(7):9838-9858. PubMed ID: 33744866
[TBL] [Abstract][Full Text] [Related]
6. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
[TBL] [Abstract][Full Text] [Related]
7. lncRNA SNHG4 inhibits ferroptosis by orchestrating miR-150-5p/c-Myb axis in colorectal cancer.
Li SQ; Lv F; Xu WT; Yin YX; Wei HT; Li KZ; Hu BL
Int J Biol Macromol; 2024 Apr; 268(Pt 2):131961. PubMed ID: 38692535
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.
Wang H; Li H; Zhang L; Yang D
Biomed Pharmacother; 2018 Oct; 106():1607-1615. PubMed ID: 30119236
[TBL] [Abstract][Full Text] [Related]
9. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
[TBL] [Abstract][Full Text] [Related]
10. Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin.
Wang Q; Chen X; Jiang Y; Liu S; Liu H; Sun X; Zhang H; Liu Z; Tao Y; Li C; Hu Y; Liu D; Ye D; Liu Y; Wang M; Zhang X
J Mol Cell Biol; 2020 Feb; 12(2):125-137. PubMed ID: 31065671
[TBL] [Abstract][Full Text] [Related]
11. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.
Gao R; Fang C; Xu J; Tan H; Li P; Ma L
Arch Biochem Biophys; 2019 Mar; 663():183-191. PubMed ID: 30639170
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA SNHG4 enhances RNF14 mRNA stability to promote the progression of colorectal cancer by recruiting TAF15 protein.
Lv L; Huang B; Yi L; Zhang L
Apoptosis; 2023 Apr; 28(3-4):414-431. PubMed ID: 36482019
[TBL] [Abstract][Full Text] [Related]
13. Metabolic targeting of HIF-1α potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer.
Wei TT; Lin YT; Tang SP; Luo CK; Tsai CT; Shun CT; Chen CC
Oncogene; 2020 Jan; 39(2):414-427. PubMed ID: 31477841
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of AC092894.1 promotes oxaliplatin resistance in colorectal cancer via the USP3/AR/RASGRP3 axis.
Zheng Z; Wu M; Li H; Xu W; Yang M; Pan K; Ni Y; Jiang T; Zheng H; Jin X; Zhang Y; Ding L; Fu J
BMC Med; 2023 Apr; 21(1):132. PubMed ID: 37013584
[TBL] [Abstract][Full Text] [Related]
15. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
[TBL] [Abstract][Full Text] [Related]
16. EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer.
Xiao Z; Liu Y; Li Q; Liu Q; Liu Y; Luo Y; Wei S
Cancer Chemother Pharmacol; 2021 Dec; 88(6):1021-1031. PubMed ID: 34599680
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells.
Deng X; Ruan H; Zhang X; Xu X; Zhu Y; Peng H; Zhang X; Kong F; Guan M
Int J Cancer; 2020 Mar; 146(6):1700-1716. PubMed ID: 31381140
[TBL] [Abstract][Full Text] [Related]
18. S100A6 mediated epithelial-mesenchymal transition affects chemosensitivity of colorectal cancer to oxaliplatin.
Zhang C; Zeng M; Xu Y; Huang B; Shi P; Zhu X; Cao Y
Gene; 2024 Jul; 914():148406. PubMed ID: 38521111
[TBL] [Abstract][Full Text] [Related]
19. CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism.
Li H; Chen J; Liu J; Lai Y; Huang S; Zheng L; Fan N
Exp Cell Res; 2021 Dec; 409(1):112892. PubMed ID: 34688609
[TBL] [Abstract][Full Text] [Related]
20. WBSCR22 confers oxaliplatin resistance in human colorectal cancer.
Yan D; Tu L; Yuan H; Fang J; Cheng L; Zheng X; Wang X
Sci Rep; 2017 Nov; 7(1):15443. PubMed ID: 29133897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
